AbbVie Inc (WBO:ABBV)
€ 148.62 -1.44 (-0.96%) Market Cap: 264.38 Bil Enterprise Value: 316.20 Bil PE Ratio: 47.40 PB Ratio: 35.22 GF Score: 91/100

Abbvie Inc at Wolfe Research Healthcare Conference (Virtual) Transcript

Nov 19, 2020 / 05:35PM GMT
Release Date Price: €83.91 (+0.04%)
Timothy Minton Anderson
Wolfe Research, LLC - MD of Equity Research

Okay. Great. Thanks for joining us. I'm Tim Anderson, the large cap pharma and biotech analyst at Wolfe Research, and for the next half an hour, we'll be talking with 3 members of AbbVie's management team.

Rick Gonzalez, who's the CEO and Chairman of the Board. He spent more than 30 years at Abbott and went to AbbVie after it split out. And he's worked, of course, in a variety of roles, commercial, R&D and manufacturing.

We have Mike Severino, who's Vice Chairman and President of AbbVie, responsible for R&D and other expanded roles within the organization. He joined the company in 2014. Prior to that, he was at Amgen and Merck.

And we have Rob Michael, who's EVP and CFO of AbbVie. Prior to that, he held a variety of roles within AbbVie and the predecessor company, Abbott, and he joined Abbott in 1993. So we're just going to jump straight into Q&A, given the limited amount of time.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot